Summary
BeiGene, Ltd. (ONC) reported its first-quarter 2019 financial results, showing significant revenue growth driven by both product sales and collaboration revenue. Total revenues more than doubled year-over-year, reaching $77.8 million. Despite this top-line growth, the company continued to experience substantial operating losses, with a net loss attributable to BeiGene, Ltd. of $167.6 million for the quarter. This widening loss is primarily due to a significant increase in research and development (R&D) expenses, which rose by 63% to $178.4 million, reflecting continued investment in the advancement of its oncology drug pipeline, including zanubrutinib, tislelizumab, and pamiparib. From a balance sheet perspective, the company maintained a strong liquidity position, with cash, cash equivalents, and short-term investments totaling $1.6 billion as of March 31, 2019. This substantial cash balance is crucial for funding ongoing R&D, expanding commercial operations in China, and preparing for potential future product launches. Investors should note the company's substantial R&D spend as it progresses its late-stage clinical candidates, which is a key driver for future potential growth but also contributes to significant ongoing losses.
Financial Highlights
52 data points| Revenue | $77.83M |
| Cost of Revenue | $15.26M |
| Gross Profit | $62.57M |
| R&D Expenses | $178.35M |
| SG&A Expenses | $57.65M |
| Operating Expenses | $251.59M |
| Operating Income | -$173.75M |
| Net Income | -$168.07M |
| EPS (Basic) | $-0.22 |
| Shares Outstanding (Basic) | 774.75M |
Key Highlights
- 1Total revenues surged by 139% to $77.8 million in Q1 2019, compared to $32.5 million in Q1 2018, driven by strong growth in both product revenue (up 147%) and collaboration revenue (up 120%).
- 2Research and Development (R&D) expenses increased by 63% to $178.4 million in Q1 2019 from $109.7 million in Q1 2018, indicating continued significant investment in the company's drug development pipeline.
- 3Selling, General, and Administrative (SG&A) expenses more than doubled, increasing by 99% to $57.6 million in Q1 2019 from $28.9 million in Q1 2018, reflecting expansion of commercial operations and the overall growth of the company.
- 4The company reported a net loss attributable to BeiGene, Ltd. of $167.6 million for the three months ended March 31, 2019, an increase from a net loss of $104.6 million in the same period of 2018.
- 5Cash, cash equivalents, and short-term investments stood at $1.6 billion as of March 31, 2019, providing substantial liquidity to fund operations and future development activities.
- 6The company adopted new lease accounting standards (ASU 2016-2), recognizing $72.6 million in operating lease right-of-use assets and $29.0 million in lease liabilities on the balance sheet as of March 31, 2019.